Quintiles in partnership with University of Malaya

Quintiles announced a strategic alliance agreement with the University Malaya Medical Centre (UMMC) as part of its Prime Site program; an initiative focused on accelerating the development of new and more effective medicines.

The UMMC is the first Prime Site in Asia for Quintiles, adding to its existing four other sites located in US, Europe and Africa.

From a clinical research standpoint, Asia has long held promise for the global bio pharmaceutical industry’s future as companies work to minimise time and cost to market, as well as capitalise on the innovation occurring throughout the region.

Anand Tharmaratnam, MD, Senior Vice President and Head of Clinical Development for Quintiles Asia-Pacific said, “Malaysia is an increasingly important player in Asia-Pacific clinical drug development and the commitment of its government, academic and private industry leaders to promoting leading-edge clinical research in the country is undeniable.”

“This, coupled with the highly skilled clinical workforce, strong clinical research infrastructure and large potential patient populations makes Malaysia and UMMC a quality fit as our first Prime Site in Asia. With the enthusiasm and vision for this model that our UMMC partner has shown, we are confident that this will serve as a strong foundation for our Prime Site program in Asia.”